ICAM1 and Schwartz-Jampel syndrome: The effect of JAK inhibitors and NAC on ICAM-1 and PD-L1 production could act beneficially in SjS, reducing activation of SGECs and subsequently reducing inflammation and lymphocytic infiltration.